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Background:  Clinical  signiﬁcance  of  statin-induced  high-density  lipoprotein  cholesterol  (HDL-C)  changes
is not  well  known.  We  investigated  the  factors  affecting  rosuvastatin-induced  HDL-C  changes  and  their
correlation  with  12-month  major  adverse  cardiovascular  events  (MACE)  in  patients  with  non-ST-segment
elevation  acute coronary  syndrome  (NSTE-ACS)  and  percutaneous  coronary  intervention  (PCI).
Materials  and  methods:  We  analyzed  556  consecutive  NSTE-ACS  patients  who  underwent  PCI and  received
rosuvastatin  10 mg  before  discharge.  We  measured  serum  lipids,  including  total  cholesterol,  triglycerides
(TGs),  low-density  lipoprotein  cholesterol  (LDL-C),  and  HDL-C  at baseline  and  at 4  weeks.  The  relationship
between  on-treatment  lipid  levels,  baseline  lipid  levels,  and  12-month  MACE  was  assessed.
Results:  Rosuvastatin  treatment  increased  the  mean  HDL-C  concentration  by  1.1 ±  9.8  mg/dl  (4.3  ±  23.0%).
HDL-C  was  increased  in  312  patients  (56.1%),  but decreased  in  244  patients  (43.9%)  after  statin  treatment.
Changes  in HDL-C  during  ﬁrst  month  were  inversely  correlated  with  baseline  HDL-C  levels  (r  =  −0.379,
p < 0.001).  The  patients  with  increased  HDL-C  showed  higher  baseline  TG  levels  but  lower  on-treatment
TG  levels.  Changes  in TG  were  correlated  with  changes  in HDL-C  (r  =  −0.212,  p <  0.001).  The incidence  of
12-month  MACE  according  to changes  in  HDL-C  was  similar  between  the  two  groups  (11.9%  vs. 12.3%,
p  = 0.875).  Multivariate  analysis  revealed  that  baseline  HDL-C  level  was  the  only  signiﬁcant  predictor  of
rosuvastatin-induced  HDL-C  changes.
Conclusion:  Baseline  HDL-C  concentration  was  an  independent  predictor  of  rosuvastatin-induced  HDL-C
changes.  Statin-induced  HDL-C  changes  did  not  predict  12-month  MACE  in patients  with  NSTE-ACS.
©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Statins are known to signiﬁcantly reduce cardiovascular clinical
vents in a variety of patients, ranging from those with established
ardiovascular disease to those who are at risk for cardiovascu-
ar disease [1–5]. The beneﬁts of statin treatment can be obtained
hrough the reduction of low-density lipoprotein cholesterol (LDL-
). However, there is circumstantial evidence that statin-induced
igh-density lipoprotein cholesterol (HDL-C) increase may  also
ontribute to the beneﬁt [6,7].
At commonly used doses, statin treatment is associated with
inor elevations in HDL-C, but the mechanism by which statins
∗ Corresponding author at: Department of Cardiovascular Medicine, The Heart
enter of Wonkwang University Hospital, 344-2 Shinyong-dong, Iksan, Jeonbuk 570-
11, Republic of Korea. Tel.: +82 63 859 2524; fax: +82 63 852 8480.
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914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.07.008increase the concentration of HDL-C has not been well established.
The HDL-C response to any given statin tends to vary widely from
study to study; however, the factors responsible are little under-
stood. Furthermore, on-treatment values of HDL-C after statin
therapy have been inconsistently correlated with the risk of car-
diovascular events [6,8–10].
A lipid-lowering trial showed that the lowest lipid level
after statin treatment is achieved after 4–6 weeks, and then
the lowered lipid level remained during the study period. So,
the lipid-lowering effect of statins was  mainly shown in the
ﬁrst month [11,12]. Therefore, we  examined the on-treatment
lipid level at baseline and at 4 weeks after initiation of the
treatment in patients with acute coronary syndrome (ACS) who
received percutaneous coronary intervention (PCI) to evaluate
factors affecting statin-induced HDL-C changes. We  also inves-
tigated whether statin-induced HDL-C changes can predict a
12-month major adverse cardiovascular event (MACE) in those
patients.
vier Ltd. All rights reserved.
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aterials and methods
ubjects and protocol
The studied patients were participants of a prospectively
nrolled, single-center, PCI with drug-eluting stent cohort. We
etrospectively analyzed 723 consecutive non-ST-segment eleva-
ion ACS (NSTE-ACS) patients who underwent PCI and received
tatin (rosuvastatin 10 mg)  before discharge between January
008 and May  2010. Exclusion criteria were ST-segment eleva-
ion myocardial infarction (MI) including true posterior MI; failed
CI; in-hospital MI  or repeated revascularization; allergy to statin;
dministration of drugs that can affect lipid levels including ﬁbrate,
sh oil, niacin, ezetimibe or probucol; known inﬂammatory, neo-
lastic, or infectious diseases; and PCI within the previous 12
onths.
PCI was performed according to current clinical practice at the
hysician’s discretion. PCI was performed within 48 h after admis-
ion. Angiographic success of PCI was deﬁned as thrombolysis in
yocardial infarction (TIMI) III ﬂow with residual stenosis below
0%. All the patients involved in the study had undergone success-
ul procedures. After the procedure, the patients received 75 mg
f clopidogrel for 12 months and aspirin indeﬁnitely. Rosuvastatin
0 mg  was administered as soon as possible after hospitalization,
egardless of baseline lipid level, and at the latest prior to discharge.
ngiotensin-converting enzyme inhibitors and beta blockers were
rescribed according to the physician’s discretion.
Total cholesterol, triglycerides (TGs), and HDL-C were measured
sing an enzymatic colorimetric assay (Roche Diagnostics, Indi-
napolis, IN, USA) after 12 h overnight fasting. LDL-C was directly
easured. Lipid and lipoprotein levels were obtained at baseline
nd at 4 weeks.
The clinical end-point was deﬁned as the occurrence of MACE,
ncluding cardiac death, non-fatal MI,  non-fatal ischemic stroke,
nd any coronary repeated revascularization (surgery or PCI). Only
he ﬁrst event was considered as end-point. A 12 month follow-up
as completed for a total of 556 patients. The remaining patients
ncluded those administered other types of statin (100 cases), those
xcluded based on the exclusion criteria (42 cases), and those with
nterrupted statin treatment (19 cases), or MACE before week 4
6 cases), as assessed through inspection of the medical records or
hrough direct contact with the patients. All patients gave informed
onsent for processing their anonymous data according to a proto-
ol approved by the Institutional Review Boards of the hospital.
tatistical analysis
All measurements are presented as mean ± standard deviation
r absolute number (percentage). The patients were divided into
wo groups according to the changes in HDL-C (increased HDL
roup [on-treatment HDL-C ≥ baseline HDL-C] and decreased HDL
roup [on-treatment HDL-C < baseline HDL-C]). Inter-group anal-
sis was done using independent t-test, 2 test and Fisher’s exact
est which were conducted using SPSS 15.0 for Windows (SPSS Inc.,
hicago, IL, USA). Relationships between changes in lipid variables
ere measured by Pearson correlation coefﬁcients. For identifying
actors potentially predicting HDL-C changes, multivariate analysis
as carried out. Multivariate analysis was used for linear regression
nalysis, including backward stepwise elimination.
The Kaplan–Meier method was used for cumulative MACE-free
urvival analysis. Hazard ratios (HRs) and 95% conﬁdence intervals
CIs) were calculated between selected patient groups; increased
DL versus decreased HDL, on-treatment HDL-C of ≥40 mg/dl
ersus <40 mg/dl, TG/HDL-C ratio of ≥3.75 versus <3.75, LDL-
/HDL-C ratio of ≥1.75 versus <1.75. Cut-off points were derived
rom the current guidelines [13,14], that is, LDL-C < 70 mg/dl,Fig. 1. Correlation between changes in HDL-C and baseline HDL-C concentrations.
HDL-C, high-density lipoprotein cholesterol.
triglyceride <150 mg/dl, and HDL-C ≥ 40 mg/dl. The effect of covari-
ates on survival times was tested by Cox proportional hazards
regression analysis. Statistical signiﬁcance was set at p < 0.05.
Results
Five hundred ﬁfty six patients treated with rosuvastatin were
identiﬁed by the study criteria. Mean on-treatment HDL-C lev-
els were 46.3 ± 11.6 mg/dl, and mean on-treatment LDL-C levels
were 73.1 ± 24.6 mg/dl. A total of 279 patients (50.2%) achieved
on-treatment LDL-C < 70 mg/dl, 485 patients (87.2%) achieved on-
treatment LDL-C < 100 mg/dl. Rosuvastatin treatment increased
mean HDL-C concentration by 1.1 ± 9.8 mg/dl (4.3 ± 23.0%). HDL-C
was increased in 312 patients (56.1%), but decreased in 244 patients
(43.9%) after statin treatment.
Baseline clinical characteristics and procedural variables
according to changes in HDL-C are shown in Table 1. There was
no signiﬁcant difference in the most relevant clinical character-
istics between the two  groups. All angiographic and procedural
characteristics were also similar between the two groups.
Baseline HDL-C levels were higher in patients with decreased
HDL-C at 1 month (49.1 ± 12.2 mg/dl vs. 42.1 ± 8.6 mg/dl, p < 0.001)
(Table 2). Changes in HDL-C during the ﬁrst month were inversely
correlated with baseline HDL-C levels (r = −0.379, p < 0.001) (Fig. 1).
The patients with increased HDL-C showed higher baseline TG lev-
els but lower on-treatment TG levels. Therefore, TG changes in
patients with increased HDL-C were more accentuated than in
patients with decreased HDL-C, and on-treatment TG/HDL ratio
was lower in patients with increased HDL-C. Baseline LDL-C levels
were similar between two groups, and changes in LDL-C correlated
with changes in HDL-C (Fig. 2). Hence, on-treatment LDL-C levels
were lower in patients with decreased HDL-C (74.9 ± 25.4 mg/dl
vs. 70.7 ± 23.3 mg/dl, p = 0.042). However, LDL-C/HDL-C ratio was
lower in patients with increased HDL-C (1.6 ± 0.6 vs. 1.8 ± 0.9,
p = 0.003).
Incidence of 12-month MACE according to changes in HDL-C
was similar between the two  groups (11.9% vs. 12.3%, p = 0.875)
(Table 3). The incidence of MACE was signiﬁcantly different in
patients divided by on-treatment TG/HDL-C ratio or LDL-C/HDL-C
ratio but not by on-treatment HDL-C level (Fig. 3). Low on-
treatment TG/HDL-C ratio was associated with decreased MACE
compared with high on-treatment TG/HDL-C (HR, 0.62; p < 0.001).
Similarly, low on-treatment LDL-C/HDL-C ratio was  associated with
decreased MACE compared with high on-treatment LDL-C/HDL-C
(HR, 0.78; p = 0.046).
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Table  1
Baseline clinical and procedural characteristics.
Increased HDL (n = 312) Decreased HDL (n = 244) p value
Age (years) 62.7 ± 10.4 62.5 ± 10.6 0.838
Male  (%) 192 (61.5) 147 (60.2) 0.757
NSTEMI (%) 81 (26.0) 71 (29.1) 0.410
Hypertension (%) 142 (45.5) 104 (42.6) 0.496
Diabetes (%) 104 (33.3) 67 (27.5) 0.136
Current smoker (%) 136 (43.6) 99 (40.6) 0.475
Previous PCI (%) 17 (5.4) 12 (4.9) 0.780
Body  mass index (kg/m2) 24.6 ± 3.0 24.7 ± 3.2 0.477
Ejection fraction (%) 59.3 ± 11.4 60.6 ± 10.2 0.182
Serum creatinine (mg/dl) 1.0 ± 0.7 1.0 ± 0.3 0.260
Peak  troponin T (ng/ml) 0.4 ± 1.0 0.5 ± 0.8 0.831
hsCRP  (mg/l) 5.5 ± 15.3 4.9 ± 10.8 0.550
Medication (%)
ACEI/ARB 288 (92.3) 225 (92.2) 0.967
Beta  blocker 212 (67.9) 169 (69.3) 0.741
Calcium antagonist 105 (33.7) 78 (32.0) 0.674
LAD  target (%) 157 (50.3) 129 (52.9) 0.680
Multi-vessel disease (%) 170 (54.5) 121 (49.6) 0.251
ACC/AHA type B2/C lesion (%) 227 (72.8) 180 (73.8) 0.789
Stent  number per patient 1.7 ± 0.9 1.7 ± 0.9 0.779
Stent  length per patient (mm)  45.3 ± 27.3 44.3 ± 26.0 0.664
Procedural complication (%) 42 (13.5) 23 (9.4) 0.142
NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; hsCRP, high sensitivity C-reactive protein; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker; LAD, left anterior descending coronary artery; ACC/AHA, American College of Cardiology/American Heart Association
lesion classiﬁcation.
Table 2
Lipid ﬁndings after statin treatment.
Increased HDL (n = 312) Decreased HDL (n = 244) p value
Baseline
Total cholesterol (mg/dl) 197.5 ± 44.6 204.1 ± 45.1 0.087
Triglyceride (mg/dl) 182.1 ± 127.7 159.7 ± 108.7 0.029
HDL-C (mg/dl) 42.1 ± 8.6 49.1 ± 12.2 <0.001
LDL-C (mg/dl) 121.5 ± 37.7 126.4 ± 37.8 0.129
TG/HDL-C ratio 4.7 ± 3.8 3.6 ± 2.7 <0.001
LDL-C/HDL-C ratio 2.9 ± 1.0 2.7 ± 1.0 0.002
On  treatment
Total cholesterol (mg/dl) 144.4 ± 32.2 135.9 ± 30.5 0.002
Triglyceride (mg/dl) 119.9 ± 62.4 130.9 ± 68.1 0.048
HDL-C (mg/dl) 49.4 ± 11.1 42.2 ± 10.9 <0.001
LDL-C (mg/dl) 74.9 ± 25.4 70.7 ± 23.3 0.042
TG/HDL-C ratio 2.6 ± 1.6 3.4 ± 2.4 <0.001
LDL-C/HDL-C ratio 1.6 ± 0.6 1.8 ± 0.9 0.003
Change in triglycerides (mg/dl) −62.2 ± 113.3 −28.8 ± 92.8 <0.001
Change in LDL-C (mg/dl) −46.5 ± 37.1 −55.7 ± 35.0 0.003
Change in HDL-C (mg/dl) +7.3 ± 7.2 −6.9 ± 6.2 <0.001
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
Table  3
12-Month major adverse cardiovascular events according to changes in HDL-C.
Increased HDL (n = 312) Decreased HDL (n = 244) p value
Death (%) 2 (0.6) 2 (0.8) 1.000
Non-fatal MI  (%) 0 (0.0) 2 (0.8) 0.192
Non-fatal stroke (%) 6 (1.9) 3 (1.2) 0.738
TVR  (%) 23 (7.4) 18 (7.4) 0.998
Any  revascularization (%) 29 (9.3) 25 (10.2) 0.707
Total  events (%) 37 (11.9) 30 (12.3) 0.875
HDL-C, high-density lipoprotein cholesterol; MI,  myocardial infarction; TVR, target vessel revascularization.
Table 4
Linear regression analysis of independent predictors of changes in HDL-C.
Coefﬁcients (beta) 95% CI p value
Baseline HDL-C −0.34 −0.41 to −0.26 <0.001
HbA1c  0.51 −0.50 to 1.01 0.074
hsCRP  0.03 −0.02 to 0.09 0.235
Body  mass index −0.12 −0.37 to 0.13 0.352
CI, conﬁdence interval; HDL-C, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin; hsCRP, high sensitivity C-reactive protein.
The  model initially included age, sex, body mass index, baseline total cholesterol, baseline triglycerides, baseline HDL-C, baseline low-density lipoprotein cholesterol, hsCRP,
fasting  glucose, and HbA1c. Only those variables that remained after backward stepwise elimination are shown in this table.
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Multivariate analysis revealed that baseline HDL-C level was  the
nly signiﬁcant predictor of changes in HDL-C (Table 4). Baseline
evels of other lipids were not predictors of changes in HDL-C in
osuvastatin-treated patients.
iscussion
The main ﬁndings of present study were that (1) rosuvastatin
reatment could modestly elevate serum HDL-C levels; but (2) only
aseline HDL-C was a strong predictor of changes in HDL-C; and
3) changes in HDL-C could not predict 12-month MACE in patients
reated with rosuvastatin 10 mg.  These observations might support
hat on-treatment HDL-C level alone was not an important target
n patients who underwent rosuvastatin treatment.
HDL-C is a well-established risk factor for coronary heart disease
CHD). The Emerging Risk Factors Collaboration provides the most
obust evidence for the association of HDL-C with cardiovascular
isk in general populations [15]. This study showed that a 15 mg/dl
ncrease in HDL-C concentration was associated with 22% reduction
n CHD risk. Statins have not only LDL-C lowering effects but also
DL-C elevating effects, whose extent varies among statins. The
echanism of statin-induced HDL elevation is complex. Since statin
enerally increases the synthesis of apolipoprotein (Apo) A-I and
DL neogenesis in the liver, the HDL-C increasing effect of statins
ay  reﬂect reverse cholesterol transport (RCT) activation [16].
In this study, the strongest predictor of the changes in HDL-
 was baseline HDL-C concentration. Similar observations have
een made in a large database of statin trials and in people treated
ith ﬁbrate [17–19]. Possible explanation is as follows. First, statin
ay  have the mechanism that decreases HDL-C. Statins inhibit
holesterol ester transfer protein (CETP), which facilitates the oper-
tion of the atherosclerosis prevention system via HDL and Apo
-I [20,21], thereby HDL-C is elevated. However, the fact that the triglycerides, and LDL-C concentrations after statin treatment. HDL-C, high-density
on-treatment level of HDL-C is much lower than that expected by
CETP inhibition suggests that statins may  have other effects that
attenuate the increase in HDL-C resulting from CETP inhibition
[17,22].  In other words, statin-induced HDL-C increases may  reﬂect
a balance between mechanisms that increase, and others that
decrease, its concentration. Second, because HDL-C metabolism
is closely related to TG metabolism, baseline HDL-C concentra-
tion was  inversely correlated with baseline TG concentration. It
is known that statin-induced decreases in plasma TG are greater
in people with elevated levels of baseline TG [23]. Reduction in
the concentration of TG-rich lipoproteins will be accompanied by
decrease in CETP-mediated transfer of cholesterol esters from HDL-
C to TG-rich lipoproteins [24]. Therefore, baseline TG level may
inﬂuence the HDL-C response to statin, rosuvastatin-induced TG
reduction being signiﬁcantly correlated with the increase in HDL-C.
Finally, it may  be nothing more than the well-recognized statistical
phenomenon of regression to the mean.
Statin-induced HDL-C elevation is known to be independent
of the LDL-C response [17]. However, our study revealed a weak
correlation between changes in HDL-C and LDL-C. Although these
ﬁndings might have resulted from the small study samples, simi-
lar observations have been made in the LDL-C/HDL-C response to
a high dose of atorvastatin [25]. Thus, it is possible that our results
corroborated those obtained with high-dose statins, because rosu-
vastatin has been shown to be highly efﬁcacious in the Korean
population [26]. Another study reported that reduced RCT capac-
ity and reduced activity of CETP after rosuvastatin occurred in
association with reduction in apolipoprotein B (ApoB) containing
lipoprotein [27]. This result suggested that decreased CETP activi-
ties after high potency statin treatment may  only reﬂect decreased
lipoproteins that are substrates of CETP. Therefore, changes in HDL-
C can correlate with changes in LDL-C or other ApoB containing
lipoprotein.
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Cig. 3. One-year event-free rates according to lipid parameters. HDL-C, high-dens
R,  hazard ratio; CI, conﬁdential interval.
Statin-induced HDL-C increase favorably affects coronary
theroma burden and may  also contribute to statin-mediated
eduction in cardiovascular events [28,29]. However, additional
eneﬁts to on-treatment HDL-C in patients undergoing high-
otency statin treatment who achieved low LDL-C are still
nknown. A meta-analysis including 299,310 participants from 108
tudies of any lipid-modifying agents questioned the relevance of
DL-C to CHD risk [10]. There were no signiﬁcant associations
etween treatment-induced change in HDL-C and risk factors for
HD events, CHD death, or total mortality after adjustment for
hanges in LDL-C. An analysis of Treating to New Targets (TNT)
tudy showed that CHD risk was signiﬁcantly different according
o quintiles of on-treatment HDL-C. However, the relation between
n-treatment HDL-C and CHD risk was attenuated and not signif-
cant in patients allocated to receive atorvastatin 80 mg  per day
6]. Analyses of the The Pravastatin or Atorvastatin Evaluation
nd Infection Therapy (PROVE IT – TIMI22) trial and Justiﬁca-
ion for the Use of Statins in Prevention: an Intervention Trial
valuating Rosuvastatin (JUPITER) trial reported that HDL-C con-
entrations were not predictive of residual CHD risk among patients
reated with potent statin therapy who attained very low con-
entrations of LDL-C [8,30].  Finally, Atherothrombosis Intervention
n Metabolic Syndrome with Low HDL/High Triglycerides: Impact
n Global Health Outcomes (AIM-HIGH) study demonstrated that
herapy to increase HDL-C has no clinical beneﬁt in patients with
therosclerotic cardiovascular disease and LDL-C of ≤70 mg/dl [31].
ur study also revealed that rosuvastatin-induced changes in HDL-
 or on-treatment HDL-C alone did not predict MACE. Therefore,oprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG,  triglyceride;
the clinical signiﬁcance of on-treatment HDL-C should be further
investigated.
A possible explanation about low predictive power of
rosuvastatin-induced changes in HDL-C or on-treatment HDL-C
on MACE will be the concept of dysfunctional HDL. Rosuvastatin
does not change Apo A-I expression in the liver, but it signiﬁcantly
reduces the catabolic rate of Apo A-I and HDL particles that contain
Apo A-I [32]. Rosuvastatin also does not change pre- HDL con-
centrations and reduces CETP activity associated with decreasing
the ability to efﬂux cholesterol from macrophages to plasma [27].
This result suggested that rosuvastatin raised dysfunctional HDL via
CETP inhibition [16]. Moreover, HDL in ACS patients has lower anti-
inﬂammatory capacity compared with controls or angina patients
[33]. Therefore, the therapeutic target should be the functionality
of HDL as well as the levels of HDL-C.
There are several limitations in the present study. First, the sta-
tistical power was weak due to the relatively small patient group
and the low event rate. Second, we  did not measure Apo A-I or Apo
B; therefore changes in the number of lipoprotein particles were not
established. Third, all the patients received powerful statin treat-
ment, hence providing a study group whose average lipid proﬁle
was well controlled below the target level. Therefore, the results
should be analyzed with caution. Fourth, although TG and HDL-C
concentrations could be inﬂuenced by therapeutic lifestyle modiﬁ-
cation, we  could not measure the extent of lifestyle modiﬁcation
including exercise and diet. However, all patients were encour-
aged to take regular exercise and diet control and educated about
lifestyle modiﬁcation during the follow-up period. Finally, it is
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nknown whether the HDL-C response to statin is similar to that
f other types of statins or of other rosuvastatin doses.
In conclusion, we demonstrated that baseline HDL-C concentra-
ion was an independent predictor of rosuvastatin-induced HDL-C
hanges. Moreover, statin-induced HDL-C changes could not pre-
ict 12-month MACE in patients with NSTE-ACS. Further studies in
arger cohorts are needed to understand the mechanism of HDL
esponse to statin and the clinical signiﬁcance of on-treatment
DL-C in patients undergoing high-potency statin therapy.
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